Carregant...
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
PURPOSE: Although EGFR-mutated patients generally do not benefit from checkpoint inhibitors (ICIs), some patients in the KEYNOTE-001 study consistently benefited from this treatment. This study investigated immune microenvironment characteristics to identify the subgroup of patients that may benefit...
Guardat en:
| Publicat a: | Lung Cancer (Auckl) |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7490071/ https://ncbi.nlm.nih.gov/pubmed/32982525 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S262822 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|